当前位置： SCI文献检索 > DRUGS & AGING期刊下所有文献 > Inhaled corticosteroids in the long-term management of patients with chronic obstructive pulmonary disease.

Inhaled corticosteroids in the long-term management of patients with chronic obstructive pulmonary disease.

Abstract：

:Chronic obstructive pulmonary disease (COPD) is a major problem in the elderly population, with approximately 10% of the population affected. Since COPD is an inflammatory disorder of the pulmonary system, corticosteroids might be expected to improve clinical outcomes of the disease. Data from large, well designed randomised clinical trials in which approximately one third of patients were > or =65 years of age indicate that inhaled corticosteroids do not modify the natural history of COPD, as measured by the rate of decline in forced expiratory volume in 1 second (FEV1). However, these same studies also suggest that corticosteroids reduce the frequency of clinical exacerbations by nearly a third (compared with placebo). This beneficial effect is particularly pronounced among those with an FEV1 less than 50% of the predicted value. Withdrawal of inhaled corticosteroids, on the other hand, leads to increased symptoms and elevates the risk of exacerbations by 50% above baseline levels. Patients' health-related quality of life is also improved by the use of inhaled corticosteroids. It is clear that inhaled corticosteroids elevate the risk of thrush, dysphonia and skin bruising by 2-fold compared with placebo. In addition, the sum of evidence suggests a modest deleterious effect for inhaled corticosteroids on bone mineral density, especially for formulations that have an increased rate of systemic absorption. However, the clinical evidence of this observation is uncertain. The effect of inhaled corticosteroids on fracture risk is controversial with some observational studies suggesting a possible association. Whether inhaled corticosteroids increase the risk of ophthalmic complications (cataracts and glaucoma) is also uncertain. In conclusion, the current evidence indicates that inhaled corticosteroid therapy produces short- and long-term clinical benefits in COPD patients with moderate-to-severe disease and should be used as adjunctive therapy for elderly patients with COPD who experience frequent exacerbations or have moderately reduced lung function.

journal_name

Drugs Aging

journal_title

Drugs & aging

authors

Sin DD,Man SF

doi

10.2165/00002512-200320120-00001

subject

Has Abstract

pub_date

2003-01-01 00:00:00

pages

867-80

issue

eissn

1170-229X

issn

1179-1969

pii

20121

journal_volume

pub_type

杂志文章,评审

在线工具

Inhaled corticosteroids in the long-term management of patients with chronic obstructive pulmonary disease.